Contemporary management of the pseudotumor cerebri syndrome

Research output: Contribution to journalArticle

Abstract

Introduction: Diagnosis and appropriate management of patients with the pseudotumor cerebri syndrome are imperative to prevent or minimize permanent visual loss and headache-related disability. Areas covered: Steps in management, including making the correct diagnosis, techniques to assess the patient's visual status, medical treatment of intracranial hypertension and the associated headaches, weight management strategies, surgical treatments and stenting are reviewed incorporating the most recent medical evidence. Expert opinion: As the pathogenesis of the pseudotumor cerebri syndrome is still unknown, many of the currently employed management strategies incorporate a 'plumbing approach' to decrease cerebrospinal fluid (CSF) pressure. The Idiopathic Intracranial Hypertension Trial (IIHTT) taught us that the disorder markedly affects visual and overall quality of life, and that reducing pressure alone is not enough to make patients well, even those considered to have 'mild' vision loss. Other than the IIHTT, the evidence supporting the use of various treatments is meager. The course of the disorder can be unpredictable, and the clinician(s) managing these patients are often uncertain about which treatments to employ. Moreover, the desired modalities and specialists are not universally available in all locations. An individualized and detailed approach to the various manifestations and nuances of the disorder is essential.

Original languageEnglish (US)
Pages (from-to)881-893
Number of pages13
JournalExpert review of neurotherapeutics
Volume19
Issue number9
DOIs
StatePublished - Sep 1 2019

Fingerprint

Pseudotumor Cerebri
Headache
Sanitary Engineering
Cerebrospinal Fluid Pressure
Intracranial Hypertension
Expert Testimony
Therapeutics
Quality of Life
Pressure
Weights and Measures

Keywords

  • Carbonic anhydrase inhibitor
  • cerebrospinal fluid shunting
  • headache treatment
  • idiopathic intracranial hypertension
  • optic nerve sheath fenestration
  • optical coherence tomography
  • papilledema
  • pseudotumor cerebri

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology
  • Pharmacology (medical)

Cite this

Contemporary management of the pseudotumor cerebri syndrome. / Friedman, Deborah I.

In: Expert review of neurotherapeutics, Vol. 19, No. 9, 01.09.2019, p. 881-893.

Research output: Contribution to journalArticle

@article{92bae0d37d564781af7047d329c70941,
title = "Contemporary management of the pseudotumor cerebri syndrome",
abstract = "Introduction: Diagnosis and appropriate management of patients with the pseudotumor cerebri syndrome are imperative to prevent or minimize permanent visual loss and headache-related disability. Areas covered: Steps in management, including making the correct diagnosis, techniques to assess the patient's visual status, medical treatment of intracranial hypertension and the associated headaches, weight management strategies, surgical treatments and stenting are reviewed incorporating the most recent medical evidence. Expert opinion: As the pathogenesis of the pseudotumor cerebri syndrome is still unknown, many of the currently employed management strategies incorporate a 'plumbing approach' to decrease cerebrospinal fluid (CSF) pressure. The Idiopathic Intracranial Hypertension Trial (IIHTT) taught us that the disorder markedly affects visual and overall quality of life, and that reducing pressure alone is not enough to make patients well, even those considered to have 'mild' vision loss. Other than the IIHTT, the evidence supporting the use of various treatments is meager. The course of the disorder can be unpredictable, and the clinician(s) managing these patients are often uncertain about which treatments to employ. Moreover, the desired modalities and specialists are not universally available in all locations. An individualized and detailed approach to the various manifestations and nuances of the disorder is essential.",
keywords = "Carbonic anhydrase inhibitor, cerebrospinal fluid shunting, headache treatment, idiopathic intracranial hypertension, optic nerve sheath fenestration, optical coherence tomography, papilledema, pseudotumor cerebri",
author = "Friedman, {Deborah I}",
year = "2019",
month = "9",
day = "1",
doi = "10.1080/14737175.2019.1660163",
language = "English (US)",
volume = "19",
pages = "881--893",
journal = "Expert Review of Neurotherapeutics",
issn = "1473-7175",
publisher = "Expert Reviews Ltd.",
number = "9",

}

TY - JOUR

T1 - Contemporary management of the pseudotumor cerebri syndrome

AU - Friedman, Deborah I

PY - 2019/9/1

Y1 - 2019/9/1

N2 - Introduction: Diagnosis and appropriate management of patients with the pseudotumor cerebri syndrome are imperative to prevent or minimize permanent visual loss and headache-related disability. Areas covered: Steps in management, including making the correct diagnosis, techniques to assess the patient's visual status, medical treatment of intracranial hypertension and the associated headaches, weight management strategies, surgical treatments and stenting are reviewed incorporating the most recent medical evidence. Expert opinion: As the pathogenesis of the pseudotumor cerebri syndrome is still unknown, many of the currently employed management strategies incorporate a 'plumbing approach' to decrease cerebrospinal fluid (CSF) pressure. The Idiopathic Intracranial Hypertension Trial (IIHTT) taught us that the disorder markedly affects visual and overall quality of life, and that reducing pressure alone is not enough to make patients well, even those considered to have 'mild' vision loss. Other than the IIHTT, the evidence supporting the use of various treatments is meager. The course of the disorder can be unpredictable, and the clinician(s) managing these patients are often uncertain about which treatments to employ. Moreover, the desired modalities and specialists are not universally available in all locations. An individualized and detailed approach to the various manifestations and nuances of the disorder is essential.

AB - Introduction: Diagnosis and appropriate management of patients with the pseudotumor cerebri syndrome are imperative to prevent or minimize permanent visual loss and headache-related disability. Areas covered: Steps in management, including making the correct diagnosis, techniques to assess the patient's visual status, medical treatment of intracranial hypertension and the associated headaches, weight management strategies, surgical treatments and stenting are reviewed incorporating the most recent medical evidence. Expert opinion: As the pathogenesis of the pseudotumor cerebri syndrome is still unknown, many of the currently employed management strategies incorporate a 'plumbing approach' to decrease cerebrospinal fluid (CSF) pressure. The Idiopathic Intracranial Hypertension Trial (IIHTT) taught us that the disorder markedly affects visual and overall quality of life, and that reducing pressure alone is not enough to make patients well, even those considered to have 'mild' vision loss. Other than the IIHTT, the evidence supporting the use of various treatments is meager. The course of the disorder can be unpredictable, and the clinician(s) managing these patients are often uncertain about which treatments to employ. Moreover, the desired modalities and specialists are not universally available in all locations. An individualized and detailed approach to the various manifestations and nuances of the disorder is essential.

KW - Carbonic anhydrase inhibitor

KW - cerebrospinal fluid shunting

KW - headache treatment

KW - idiopathic intracranial hypertension

KW - optic nerve sheath fenestration

KW - optical coherence tomography

KW - papilledema

KW - pseudotumor cerebri

UR - http://www.scopus.com/inward/record.url?scp=85072546343&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072546343&partnerID=8YFLogxK

U2 - 10.1080/14737175.2019.1660163

DO - 10.1080/14737175.2019.1660163

M3 - Article

C2 - 31478394

AN - SCOPUS:85072546343

VL - 19

SP - 881

EP - 893

JO - Expert Review of Neurotherapeutics

JF - Expert Review of Neurotherapeutics

SN - 1473-7175

IS - 9

ER -